相似文献
1
Comment: Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Ann Pharmacother. 2009 Feb;43(2):391-2; author reply 392-3. doi: 10.1345/aph.1K666a.
2
Controversy over the cardiovascular effects of thiazolidinediones.
Am J Med. 2008 Apr;121(4):e9. doi: 10.1016/j.amjmed.2007.10.035.
3
Faster publication isn't always better.
Nat Clin Pract Cardiovasc Med. 2007 Jul;4(7):345. doi: 10.1038/ncpcardio0942.
4
[Rosiglitazone--statistics for benefits and problems].
Tidsskr Nor Laegeforen. 2007 Oct 18;127(20):2702-3.
5
Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation.
J Am Coll Cardiol. 2010 Apr 27;55(17):1885-94. doi: 10.1016/j.jacc.2010.02.014.
6
Thiazolidinediones and cardiovascular risk: will the evidence so far available modify treatment strategies for type 2 diabetes?
Nutr Metab Cardiovasc Dis. 2008 Feb;18(2):85-7. doi: 10.1016/j.numecd.2008.01.003. Epub 2008 Feb 15.
7
Is there clear and convincing evidence of cardiovascular risk with rosiglitazone?
Clin Pharmacol Ther. 2011 Jun;89(6):773-6. doi: 10.1038/clpt.2011.65.
8
[Pioglitazone in evaluation by IQWiG (Institute for Quality and Cost Effectiveness in Public Health)--tunnel vision instead of broad view].
MMW Fortschr Med. 2008 Aug 28;150(32-35):56-7.
9
[Glitazone - mailing no 1. In response to DMW 49/2007].
Dtsch Med Wochenschr. 2008 Feb;133(6):261; author reply 262-3. doi: 10.1055/s-2008-1017508.
10
[Glitazone - mailing no 3. In response to DMW 49/2007].
Dtsch Med Wochenschr. 2008 Feb;133(6):261-2; author reply 262-3. doi: 10.1055/s-2008-1017510.
Zotero 插件